Severe Vincristine-Induced Peripheral Neuropathic Weakness in Both Lower Limbs in an Asian Adolescent with CYP3A4 rs2740574 TT Genotype

References

• Martino E, Casamassima G, Castiglione S, et al. Vinca alkaloids and analogues as anti-cancer agents: looking back, peering ahead. Bioorg Med Chem Lett. 2018;28(17):2816–2826. doi:10.1016/j.bmcl.2018.06.044
   PubMed Web of Science ®Google Scholar
• Triarico S, Romano A, Attinà G, et al. Vincristine-Induced Peripheral Neuropathy (VIPN) in pediatric tumors: mechanisms, risk factors, strategies of prevention and treatment. Int J Mol Sci. 2021;22(8):4112. doi:10.3390/ijms22084112
   PubMed Web of Science ®Google Scholar
• Tay CG, Lee VWM, Ong LC, Goh KJ, Ariffin H, Fong CY. Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2017;64(8). doi:10.1002/pbc.26471
   PubMed Web of Science ®Google Scholar
• Li T, Kandula T, Cohn RJ, Kiernan MC, Park SB, Farrar MA. Prospective assessment of vincristine-induced peripheral neuropathy in paediatric acute lymphoblastic leukemia. Clin Neurophysiol. 2023;154:157–168. doi:10.1016/j.clinph.2023.08.002
   PubMed Web of Science ®Google Scholar
• Gilbert A, Piccinin C, Velikova G, et al. Linking the European organisation for research and treatment of cancer item library to the common terminology criteria for adverse events. J Clin Oncol. 2022;40(32):3770–3780. doi:10.1200/JCO.21.02017
   PubMed Web of Science ®Google Scholar
• Lavoie Smith EM, Li L, Hutchinson RJ, et al. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs. 2013;36(5):E49–E60. doi:10.1097/NCC.0b013e318299ad23
   PubMed Web of Science ®Google Scholar
• Yang QY, Hu YH, Guo HL, et al. Vincristine-induced peripheral neuropathy in childhood acute lymphoblastic leukemia: genetic variation as a potential risk factor. Front Pharmacol. 2021;12:771487. doi:10.3389/fphar.2021.771487
   PubMed Web of Science ®Google Scholar
• van de Velde ME, Kaspers GL, Abbink FCH, Wilhelm AJ, Ket JCF, van den Berg MH. Vincristine-induced peripheral neuropathy in children with cancer: a systematic review. Crit Rev Oncol/Hematol. 2017;114:114–130. doi:10.1016/j.critrevonc.2017.04.004
   PubMed Web of Science ®Google Scholar
• Tunjungsari DA, Gunawan PI, Ugrasena IDG. Risk factors of vincristine-induced peripheral neuropathy in acute lymphoblastic leukaemia children. J Med Invest. 2021;68(3–4):232–237. doi:10.2152/jmi.68.232
   PubMed Web of Science ®Google Scholar
• Kus T, Aktas G, Kalender ME, et al. Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco Targets Ther. 2016;9:5073–5080. doi:10.2147/OTT.S106574
   PubMed Web of Science ®Google Scholar
• Ma XL, Tang JY. 中国儿童及青少年横纹肌肉瘤诊疗建议(cccg-rms-2016)解读 [Interpretation of recommendations for the diagnosis and treatment of rhabdomyosarcoma in Chinese children and adolescents (CCCG-RMS-2016)]. Zhonghua er ke za zhi. 2017;55(10):735–737. Chinese.
   PubMedGoogle Scholar
• Jain P, Gulati S, Seth R, Bakhshi S, Toteja GS, Pandey RM. Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics. J Child Neurol. 2014;29(7):932–937. doi:10.1177/0883073813491829
   PubMed Web of Science ®Google Scholar
• Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63(6):419–437. doi:10.3322/caac.21204
   PubMed Web of Science ®Google Scholar
• Madsen ML, Due H, Ejskjær N, Jensen P, Madsen J, Dybkær K. Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review. Cancer Chemother Pharmacol. 2019;84(3):471–485. doi:10.1007/s00280-019-03884-5
   PubMed Web of Science ®Google Scholar
• Rosca L, Robert-Boire V, Delisle JF, Samson Y, Perreault S. Carboplatin and vincristine neurotoxicity in the treatment of pediatric low-grade gliomas. Pediatr Blood Cancer. 2018;65(11):e27351. doi:10.1002/pbc.27351
   PubMed Web of Science ®Google Scholar
• Kellie SJ, Koopmans P, Earl J, et al. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer. 2004;100(12):2637–2643. doi:10.1002/cncr.20220
   PubMedGoogle Scholar
• van de Velde ME, Kaspers GJL, Abbink FCH, et al. Vincristine-induced peripheral neuropathy in pediatric oncology: a randomized controlled trial comparing push injections with one-hour infusions (The VINCA Trial). Cancers. 2020;12(12):3745. doi:10.3390/cancers12123745
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Arena R, Battista A, Rizzo D, Attinà G, Riccardi R. Azole interactions with multidrug therapy in pediatric oncology. Eur J Clin Pharmacol. 2013;69(1):1–10. doi:10.1007/s00228-012-1310-x
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet. 2001;27(4):383–391. doi:10.1038/86882
   PubMed Web of Science ®Google Scholar
• Sims RP. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia. J Oncol Pharm Pract. 2016;22(1):76–81. doi:10.1177/1078155214553143
   PubMedGoogle Scholar
• Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006;34(8):1317–1327. doi:10.1124/dmd.106.009902
   PubMed Web of Science ®Google Scholar
• Uittenboogaard A, Neutel CLG, Ket JCF, et al. Pharmacogenomics of vincristine-induced peripheral neuropathy in children with cancer: a systematic review and meta-analysis. Cancers. 2022;14(3):612. doi:10.3390/cancers14030612
   PubMed Web of Science ®Google Scholar
• Ceppi F, Langlois-Pelletier C, Gagné V, et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15(8):1105–1116. doi:10.2217/pgs.14.68
   PubMed Web of Science ®Google Scholar
• Guilhaumou R, Solas C, Bourgarel-Rey V, et al. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol. 2011;68(6):1633–1638. doi:10.1007/s00280-011-1745-2
   PubMed Web of Science ®Google Scholar
• Apellániz-Ruiz M, Lee MY, Sánchez-Barroso L, et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clin Cancer Res. 2015;21(2):322–328. doi:10.1158/1078-0432.CCR-14-1758
   PubMed Web of Science ®Google Scholar
• Stock W, Diouf B, Crews KR, et al. An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther. 2017;101(3):391–395. doi:10.1002/cpt.506
   PubMed Web of Science ®Google Scholar
• Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313(8):815–823. doi:10.1001/jama.2015.0894
   PubMed Web of Science ®Google Scholar
• Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E, et al. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharm Genom. 2016;26(2):100–102. doi:10.1097/FPC.0000000000000191
   PubMed Web of Science ®Google Scholar
• Diouf B, Evans WE. Pharmacogenomics of vincristine-induced peripheral neuropathy: progress continues. Clin Pharmacol Ther. 2019;105(2):315–317. doi:10.1002/cpt.1209
   PubMed Web of Science ®Google Scholar
• Wright GEB, Amstutz U, Drögemöller BI, et al. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. 2019;105(2):402–410. doi:10.1002/cpt.1179
   PubMed Web of Science ®Google Scholar
• Sajdyk TJ, Boyle FA, Foran KS, et al. Obesity as a potential risk factor for vincristine-induced peripheral neuropathy. J Pediat Hematol Oncol. 2020;42(7):e637–e640. doi:10.1097/MPH.0000000000001604
   PubMed Web of Science ®Google Scholar
• Edwards JK, Bossaer JB, Lewis PO, Sant A. Peripheral neuropathy in non-Hodgkin’s lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant. J Oncol Pharm Pract. 2020;26(4):809–813. doi:10.1177/1078155219870840
   PubMed Web of Science ®Google Scholar
• Aydin Köker S, Gözmen S, Demirağ B, et al. Effect of pyridoxine plus pyridostigmine treatment on vincristine-induced peripheral neuropathy in pediatric patients with acute lymphoblastic leukemia: a single-center experience. Neurol Sci. 2021;42(9):3681–3686. doi:10.1007/s10072-020-04970-w
   PubMed Web of Science ®Google Scholar
• Sands S, Ladas EJ, Kelly KM, et al. Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. Support Care Cancer. 2017;25(3):701–708. doi:10.1007/s00520-016-3441-6
   PubMed Web of Science ®Google Scholar
• Maihöfner C, Diel I, Tesch H, Quandel T, Baron R. Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin. Support Care Cancer. 2021;29(8):4223–4238. doi:10.1007/s00520-021-06042-x
   PubMed Web of Science ®Google Scholar